Roche May Refine Long-Acting EPO Development Based On FDA Advisory Committee Outcome
This article was originally published in The Pink Sheet Daily
An Oncologic Drugs Advisory Committee meeting on safety issues associated with Amgen's Aranesp and J&J's Procrit could affect the Phase III program for long-acting erythropoietin, Roche says.
You may also be interested in...
Studies have raised questions about the angiogenic potential of erythropoietin and its role in tumor hypoxia. Oncologic Drugs Advisory Committee is not expected to address cases of pure red blood cell aplasia.
Continuous-acting erythropoietin CERA and rheumatoid arthritis agent MRA will join ovarian cancer treatment pemtumomab to give Roche a total of three novel Phase III agents in 2004. All three biotech agents are projected for filing in next five years.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.